About The Study: Among people with insulin-naive type 2 diabetes, once-weekly icodec demonstrated superior HbA1c reduction to once-daily degludec after 26 weeks of treatment, with no difference in weight change and a higher rate of combined level two or three hypoglycemic events in the context of less than one event per patient-year exposure in both groups.
Authors: Ildiko Lingvay, M.D., of the University of Texas Southwestern Medical Center in Dallas, and Yiming Mu, M.D., of the Chinese People’s Liberation Army General Hospital in Beijing, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.11313)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the American Diabetes Association’s 83rd Scientific Sessions.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.11313?guestAccessKey=0cee36ed-e667-4cf9-9535-edfdf510b81b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062423
Journal
JAMA